<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT00093600">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00093600">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT00093600 on 2005_08_01</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Protocol</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00093600/2005_07_25/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00093600/2005_07_25">(Updated 2005_07_25)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00093600/2005_09_09/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00093600/2005_08_01">(Updated 2005_08_01)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  CDR0000389242</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NOVARTIS-CPKC412A2106</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  CDR0000389242</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NOVARTIS-CPKC412A2106</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3">PKC412, Daunorubicin, and Cytarabine in Treating Patients <span class="sdwc">with</span> Newly Diagnosed Acute Myeloid Leukemia </div>
</td>
<td class="sdiff-b"><div class="sdl3">PKC412,  Daunorubicin,  and  Cytarabine  in  Treating  Patients  <span class="sdwc">With</span> Newly  Diagnosed  Acute  Myeloid  Leukemia  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f27A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f27&#39;)" style="display:none" /><img id="sdiff-collapse-f27A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f27&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f27A-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f27&#39;)" style="display:none"></div><div id="sdiff-collapse-f27A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f27B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f27&#39;)" style="display:none" /><img id="sdiff-collapse-f27B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f27&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f27B-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f27&#39;)" style="display:none"></div><div id="sdiff-collapse-f27B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3">Phase I Study of PKC412 Administered Sequentially <span class="sdwc">Or</span> Concurrently <span class="sdwc">with</span> Induction Chemotherapy Comprising Daunorubicin and Cytarabine Followed <span class="sdwc">by</span> Consolidation Therapy Comprising High-Dose Cytarabine in Patients <span class="sdwc">with</span> Newly Diagnosed Acute Myeloid Leukemia </div>
</td>
<td class="sdiff-b"><div class="sdl3">Phase  I  Study  of  PKC412  Administered  Sequentially  <span class="sdwc">or</span> Concurrently  <span class="sdwc">With</span> Induction  Chemotherapy  Comprising  Daunorubicin  and  Cytarabine  Followed  <span class="sdwc">By</span> Consolidation  Therapy  Comprising  High-Dose  Cytarabine  in  Patients  <span class="sdwc">With</span> Newly  Diagnosed  Acute  Myeloid  Leukemia  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f32A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f32&#39;)" style="display:none" /><img id="sdiff-collapse-f32A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f32&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f32A-cdiv" class="sdiff-collapsed" title="The middle 333 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f32&#39;)" style="display:none"></div><div id="sdiff-collapse-f32A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Federal Government</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells.</div>
<div class="sdl3">  </div>
<div class="sdl3">  PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  OBJECTIVES: </div>
<div class="sdl3">  Primary</div>
<div class="sdl3">    - Determine the safety and tolerability of PKC412 administered sequentially or concurrently with induction chemotherapy comprising daunorubicin and cytarabine followed by consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl3">    - Compare the pharmacokinetics of these regimens in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Secondary</div>
<div class="sdl3">    - Determine the efficacy of these regimens, in terms of response rate, disease-free survival, and overall survival, in these patients.</div>
<div class="sdl3">    - Correlate genetic variation in drug metabolism genes, leukemia genes, and drug target genes with response in patients treated with these regimens.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is an open-label, multicenter study. Patients are alternately assigned to 1 of 2 induction treatment groups.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        - Group I (sequential therapy): Patients receive daunorubicin IV over 30 minutes on days 1-3, cytarabine IV continuously on days 1-7, and oral PKC412 twice daily on days 8-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">        - Group II (concurrent therapy): Patients receive daunorubicin and cytarabine as in group I and oral PKC412 twice daily on days 1-7 and 15-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">      In both groups, patients are evaluated on day 28. Patients with persistent disease receive a second induction course comprising daunorubicin IV over 30 minutes on days 1 and 2, cytarabine IV continuously on days 1-5, and oral PKC412 on the same schedule as their assigned treatment group. Patients with a complete response after course 1 or course 2 proceed to consolidation therapy.</div>
<div class="sdl3">  </div>
<div class="sdl3">    - Consolidation therapy: Patients in both groups receive high-dose cytarabine IV over 3 hours twice daily on days 1, 3, and 5 and oral PKC412 on the same schedule as their assigned treatment group. Treatment repeats every 28-42 days for 3 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  After completion of consolidation therapy, patients in both groups continue to receive PKC412 alone, according to their assigned treatment group, every 28-42 days for up to 3 years in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients are followed every 3 months.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 12-52 patients (6-26 per treatment group) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-09</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with 11q23 (MLL) abnormalities</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with inv(16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(15;17)(q22;q12)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(16;16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(8;21)(q22;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  untreated adult acute myeloid leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  PKC412</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  daunorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemosensitization/potentiation</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  enzyme inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  high-dose chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  protein tyrosine kinase inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS: </div>
<div class="sdl4">    - Histologically confirmed acute myeloid leukemia (AML)</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Newly diagnosed disease</div>
<div class="sdl4">    - No history of or newly diagnosed myelodysplastic syndromes, history of myeloproliferative disease, or secondary AML</div>
<div class="sdl4">    - No CNS malignancy</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS: </div>
<div class="sdl4">  Age</div>
<div class="sdl4">    - 18 to 60</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status</div>
<div class="sdl4">    - Karnofsky 70-100%</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic</div>
<div class="sdl4">    - AST and ALT &amp;#8804; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - Bilirubin &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No active viral hepatitis</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal</div>
<div class="sdl4">    - Creatinine &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No chronic renal disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular</div>
<div class="sdl4">    - Ejection fraction &amp;#8805; 50% by MUGA or echocardiogram</div>
<div class="sdl4">    - No congestive heart failure</div>
<div class="sdl4">    - No myocardial infarction within the past 6 months</div>
<div class="sdl4">    - No poorly controlled hypertension</div>
<div class="sdl4">    - No other cardiovascular disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary</div>
<div class="sdl4">    - No pulmonary infiltrate, including those suspected to be infectious</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Patients with pulmonary infection whose clinical symptoms have resolved are eligible provided there are no residual pulmonary infiltrates on chest x-ray</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - No gastrointestinal impairment or disease that would preclude absorption of study drugs</div>
<div class="sdl4">    - No uncontrolled diabetes</div>
<div class="sdl4">    - No active uncontrolled infection</div>
<div class="sdl4">    - No other disease, except carcinoma , that would preclude study participation</div>
<div class="sdl4">    - No other severe or uncontrolled medical condition that would preclude study participation</div>
<div class="sdl4">    - HIV negative</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective barrier contraception during and for 3 months after study participation</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR CONCURRENT THERAPY: </div>
<div class="sdl4">  Biologic therapy</div>
<div class="sdl4">    - At least 5 days since prior growth factors</div>
<div class="sdl4">    - No concurrent biological response modifiers</div>
<div class="sdl4">  </div>
<div class="sdl4">  Chemotherapy</div>
<div class="sdl4">    - No prior chemotherapy</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Endocrine therapy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Radiotherapy</div>
<div class="sdl4">    - No prior radiotherapy except radiation castration</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Surgery</div>
<div class="sdl4">    - More than 14 days since prior surgical procedure except central venous catheter placement or other minor procedure (e.g., skin biopsy)</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - More than 30 days since prior investigational agents</div>
<div class="sdl4">    - No other concurrent anticancer agents</div>
<div class="sdl4">    - No other concurrent investigational drugs</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Ronald Paquette, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center at UCLA</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center at UCLA</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Los Angeles</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  California</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  90095-1678</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Ronald Paquette, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  310-825-5608</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  paquette@ucla.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Clinical trial summary from the National Cancer Institute&amp;apos;s PDQ&amp;#174; database</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://cancer.gov/clinicaltrials/UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-10-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2005-06-23</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f32B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f32&#39;)" style="display:none" /><img id="sdiff-collapse-f32B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f32&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-f32B-cdiv" class="sdiff-collapsed" title="The middle 333 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f32&#39;)" style="display:none"></div><div id="sdiff-collapse-f32B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Federal Government</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells.</div>
<div class="sdl3">  </div>
<div class="sdl3">  PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  OBJECTIVES: </div>
<div class="sdl3">  Primary</div>
<div class="sdl3">    - Determine the safety and tolerability of PKC412 administered sequentially or concurrently with induction chemotherapy comprising daunorubicin and cytarabine followed by consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl3">    - Compare the pharmacokinetics of these regimens in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Secondary</div>
<div class="sdl3">    - Determine the efficacy of these regimens, in terms of response rate, disease-free survival, and overall survival, in these patients.</div>
<div class="sdl3">    - Correlate genetic variation in drug metabolism genes, leukemia genes, and drug target genes with response in patients treated with these regimens.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is an open-label, multicenter study. Patients are alternately assigned to 1 of 2 induction treatment groups.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        - Group I (sequential therapy): Patients receive daunorubicin IV over 30 minutes on days 1-3, cytarabine IV continuously on days 1-7, and oral PKC412 twice daily on days 8-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">        - Group II (concurrent therapy): Patients receive daunorubicin and cytarabine as in group I and oral PKC412 twice daily on days 1-7 and 15-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">      In both groups, patients are evaluated on day 28. Patients with persistent disease receive a second induction course comprising daunorubicin IV over 30 minutes on days 1 and 2, cytarabine IV continuously on days 1-5, and oral PKC412 on the same schedule as their assigned treatment group. Patients with a complete response after course 1 or course 2 proceed to consolidation therapy.</div>
<div class="sdl3">  </div>
<div class="sdl3">    - Consolidation therapy: Patients in both groups receive high-dose cytarabine IV over 3 hours twice daily on days 1, 3, and 5 and oral PKC412 on the same schedule as their assigned treatment group. Treatment repeats every 28-42 days for 3 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  After completion of consolidation therapy, patients in both groups continue to receive PKC412 alone, according to their assigned treatment group, every 28-42 days for up to 3 years in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients are followed every 3 months.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 12-52 patients (6-26 per treatment group) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-09</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with 11q23 (MLL) abnormalities</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with inv(16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(15;17)(q22;q12)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(16;16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(8;21)(q22;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  untreated adult acute myeloid leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  PKC412</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  daunorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemosensitization/potentiation</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  enzyme inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  high-dose chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  protein tyrosine kinase inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS: </div>
<div class="sdl4">    - Histologically confirmed acute myeloid leukemia (AML)</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Newly diagnosed disease</div>
<div class="sdl4">    - No history of or newly diagnosed myelodysplastic syndromes, history of myeloproliferative disease, or secondary AML</div>
<div class="sdl4">    - No CNS malignancy</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS: </div>
<div class="sdl4">  Age</div>
<div class="sdl4">    - 18 to 60</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status</div>
<div class="sdl4">    - Karnofsky 70-100%</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic</div>
<div class="sdl4">    - AST and ALT &amp;#8804; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - Bilirubin &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No active viral hepatitis</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal</div>
<div class="sdl4">    - Creatinine &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No chronic renal disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular</div>
<div class="sdl4">    - Ejection fraction &amp;#8805; 50% by MUGA or echocardiogram</div>
<div class="sdl4">    - No congestive heart failure</div>
<div class="sdl4">    - No myocardial infarction within the past 6 months</div>
<div class="sdl4">    - No poorly controlled hypertension</div>
<div class="sdl4">    - No other cardiovascular disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary</div>
<div class="sdl4">    - No pulmonary infiltrate, including those suspected to be infectious</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Patients with pulmonary infection whose clinical symptoms have resolved are eligible provided there are no residual pulmonary infiltrates on chest x-ray</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - No gastrointestinal impairment or disease that would preclude absorption of study drugs</div>
<div class="sdl4">    - No uncontrolled diabetes</div>
<div class="sdl4">    - No active uncontrolled infection</div>
<div class="sdl4">    - No other disease, except carcinoma , that would preclude study participation</div>
<div class="sdl4">    - No other severe or uncontrolled medical condition that would preclude study participation</div>
<div class="sdl4">    - HIV negative</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective barrier contraception during and for 3 months after study participation</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR CONCURRENT THERAPY: </div>
<div class="sdl4">  Biologic therapy</div>
<div class="sdl4">    - At least 5 days since prior growth factors</div>
<div class="sdl4">    - No concurrent biological response modifiers</div>
<div class="sdl4">  </div>
<div class="sdl4">  Chemotherapy</div>
<div class="sdl4">    - No prior chemotherapy</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Endocrine therapy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Radiotherapy</div>
<div class="sdl4">    - No prior radiotherapy except radiation castration</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Surgery</div>
<div class="sdl4">    - More than 14 days since prior surgical procedure except central venous catheter placement or other minor procedure (e.g., skin biopsy)</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - More than 30 days since prior investigational agents</div>
<div class="sdl4">    - No other concurrent anticancer agents</div>
<div class="sdl4">    - No other concurrent investigational drugs</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Ronald Paquette, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center at UCLA</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center at UCLA</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Los Angeles</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  California</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  90095-1678</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Ronald Paquette, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  310-825-5608</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  paquette@ucla.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Clinical trial summary from the National Cancer Institute&amp;apos;s PDQ&amp;#174; database</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://cancer.gov/clinicaltrials/UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-10-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2005-06-23</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00093600/2005_07_25/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00093600/2005_07_25">(Updated 2005_07_25)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00093600/2005_09_09/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00093600/2005_08_01">(Updated 2005_08_01)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  CDR0000389242</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NOVARTIS-CPKC412A2106</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 24 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NCI</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Cancer Institute (NCI)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  CDR0000389242</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NOVARTIS-CPKC412A2106</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00093600</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3">PKC412, Daunorubicin, and Cytarabine in Treating Patients <span class="sdwc">with</span> Newly Diagnosed Acute Myeloid Leukemia </div>
</td>
<td class="sdiff-b"><div class="sdl3">PKC412,  Daunorubicin,  and  Cytarabine  in  Treating  Patients  <span class="sdwc">With</span> Newly  Diagnosed  Acute  Myeloid  Leukemia  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m27A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m27&#39;)" style="display:none" /><img id="sdiff-collapse-m27A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m27&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m27A-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m27&#39;)" style="display:none"></div><div id="sdiff-collapse-m27A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m27B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m27&#39;)" style="display:none" /><img id="sdiff-collapse-m27B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m27&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m27B-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m27&#39;)" style="display:none"></div><div id="sdiff-collapse-m27B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
</div><div class="sdl2 sds">&lt;textblock&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3">Phase I Study of PKC412 Administered Sequentially <span class="sdwc">Or</span> Concurrently <span class="sdwc">with</span> Induction Chemotherapy Comprising Daunorubicin and Cytarabine Followed <span class="sdwc">by</span> Consolidation Therapy Comprising High-Dose Cytarabine in Patients <span class="sdwc">with</span> Newly Diagnosed Acute Myeloid Leukemia </div>
</td>
<td class="sdiff-b"><div class="sdl3">Phase  I  Study  of  PKC412  Administered  Sequentially  <span class="sdwc">or</span> Concurrently  <span class="sdwc">With</span> Induction  Chemotherapy  Comprising  Daunorubicin  and  Cytarabine  Followed  <span class="sdwc">By</span> Consolidation  Therapy  Comprising  High-Dose  Cytarabine  in  Patients  <span class="sdwc">With</span> Newly  Diagnosed  Acute  Myeloid  Leukemia  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m32A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m32&#39;)" style="display:none" /><img id="sdiff-collapse-m32A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m32&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m32A-cdiv" class="sdiff-collapsed" title="The middle 296 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m32&#39;)" style="display:none"></div><div id="sdiff-collapse-m32A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Federal Government</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells.</div>
<div class="sdl3">  </div>
<div class="sdl3">  PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  OBJECTIVES: </div>
<div class="sdl3">  Primary</div>
<div class="sdl3">    - Determine the safety and tolerability of PKC412 administered sequentially or concurrently with induction chemotherapy comprising daunorubicin and cytarabine followed by consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl3">    - Compare the pharmacokinetics of these regimens in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Secondary</div>
<div class="sdl3">    - Determine the efficacy of these regimens, in terms of response rate, disease-free survival, and overall survival, in these patients.</div>
<div class="sdl3">    - Correlate genetic variation in drug metabolism genes, leukemia genes, and drug target genes with response in patients treated with these regimens.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is an open-label, multicenter study. Patients are alternately assigned to 1 of 2 induction treatment groups.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        - Group I (sequential therapy): Patients receive daunorubicin IV over 30 minutes on days 1-3, cytarabine IV continuously on days 1-7, and oral PKC412 twice daily on days 8-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">        - Group II (concurrent therapy): Patients receive daunorubicin and cytarabine as in group I and oral PKC412 twice daily on days 1-7 and 15-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">      In both groups, patients are evaluated on day 28. Patients with persistent disease receive a second induction course comprising daunorubicin IV over 30 minutes on days 1 and 2, cytarabine IV continuously on days 1-5, and oral PKC412 on the same schedule as their assigned treatment group. Patients with a complete response after course 1 or course 2 proceed to consolidation therapy.</div>
<div class="sdl3">  </div>
<div class="sdl3">    - Consolidation therapy: Patients in both groups receive high-dose cytarabine IV over 3 hours twice daily on days 1, 3, and 5 and oral PKC412 on the same schedule as their assigned treatment group. Treatment repeats every 28-42 days for 3 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  After completion of consolidation therapy, patients in both groups continue to receive PKC412 alone, according to their assigned treatment group, every 28-42 days for up to 3 years in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients are followed every 3 months.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 12-52 patients (6-26 per treatment group) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-09</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with 11q23 (MLL) abnormalities</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with inv(16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(15;17)(q22;q12)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(16;16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(8;21)(q22;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  untreated adult acute myeloid leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  PKC412</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  daunorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemosensitization/potentiation</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  enzyme inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  high-dose chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  protein tyrosine kinase inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS: </div>
<div class="sdl4">    - Histologically confirmed acute myeloid leukemia (AML)</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Newly diagnosed disease</div>
<div class="sdl4">    - No history of or newly diagnosed myelodysplastic syndromes, history of myeloproliferative disease, or secondary AML</div>
<div class="sdl4">    - No CNS malignancy</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS: </div>
<div class="sdl4">  Age</div>
<div class="sdl4">    - 18 to 60</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status</div>
<div class="sdl4">    - Karnofsky 70-100%</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic</div>
<div class="sdl4">    - AST and ALT &amp;#8804; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - Bilirubin &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No active viral hepatitis</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal</div>
<div class="sdl4">    - Creatinine &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No chronic renal disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular</div>
<div class="sdl4">    - Ejection fraction &amp;#8805; 50% by MUGA or echocardiogram</div>
<div class="sdl4">    - No congestive heart failure</div>
<div class="sdl4">    - No myocardial infarction within the past 6 months</div>
<div class="sdl4">    - No poorly controlled hypertension</div>
<div class="sdl4">    - No other cardiovascular disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary</div>
<div class="sdl4">    - No pulmonary infiltrate, including those suspected to be infectious</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Patients with pulmonary infection whose clinical symptoms have resolved are eligible provided there are no residual pulmonary infiltrates on chest x-ray</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - No gastrointestinal impairment or disease that would preclude absorption of study drugs</div>
<div class="sdl4">    - No uncontrolled diabetes</div>
<div class="sdl4">    - No active uncontrolled infection</div>
<div class="sdl4">    - No other disease, except carcinoma , that would preclude study participation</div>
<div class="sdl4">    - No other severe or uncontrolled medical condition that would preclude study participation</div>
<div class="sdl4">    - HIV negative</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective barrier contraception during and for 3 months after study participation</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR CONCURRENT THERAPY: </div>
<div class="sdl4">  Biologic therapy</div>
<div class="sdl4">    - At least 5 days since prior growth factors</div>
<div class="sdl4">    - No concurrent biological response modifiers</div>
<div class="sdl4">  </div>
<div class="sdl4">  Chemotherapy</div>
<div class="sdl4">    - No prior chemotherapy</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Endocrine therapy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Radiotherapy</div>
<div class="sdl4">    - No prior radiotherapy except radiation castration</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Surgery</div>
<div class="sdl4">    - More than 14 days since prior surgical procedure except central venous catheter placement or other minor procedure (e.g., skin biopsy)</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - More than 30 days since prior investigational agents</div>
<div class="sdl4">    - No other concurrent anticancer agents</div>
<div class="sdl4">    - No other concurrent investigational drugs</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Ronald Paquette, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center at UCLA</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Clinical trial summary from the National Cancer Institute&amp;apos;s PDQ&amp;#174; database</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://cancer.gov/clinicaltrials/UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-10-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2005-06-23</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m32B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m32&#39;)" style="display:none" /><img id="sdiff-collapse-m32B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m32&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div id="sdiff-collapse-m32B-cdiv" class="sdiff-collapsed" title="The middle 296 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m32&#39;)" style="display:none"></div><div id="sdiff-collapse-m32B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl2 sds">&lt;sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Federal Government</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells.</div>
<div class="sdl3">  </div>
<div class="sdl3">  PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  OBJECTIVES: </div>
<div class="sdl3">  Primary</div>
<div class="sdl3">    - Determine the safety and tolerability of PKC412 administered sequentially or concurrently with induction chemotherapy comprising daunorubicin and cytarabine followed by consolidation therapy comprising high-dose cytarabine in patients with newly diagnosed acute myeloid leukemia.</div>
<div class="sdl3">    - Compare the pharmacokinetics of these regimens in these patients.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Secondary</div>
<div class="sdl3">    - Determine the efficacy of these regimens, in terms of response rate, disease-free survival, and overall survival, in these patients.</div>
<div class="sdl3">    - Correlate genetic variation in drug metabolism genes, leukemia genes, and drug target genes with response in patients treated with these regimens.</div>
<div class="sdl3">  </div>
<div class="sdl3">  OUTLINE: This is an open-label, multicenter study. Patients are alternately assigned to 1 of 2 induction treatment groups.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        - Group I (sequential therapy): Patients receive daunorubicin IV over 30 minutes on days 1-3, cytarabine IV continuously on days 1-7, and oral PKC412 twice daily on days 8-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">        - Group II (concurrent therapy): Patients receive daunorubicin and cytarabine as in group I and oral PKC412 twice daily on days 1-7 and 15-21 in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">      In both groups, patients are evaluated on day 28. Patients with persistent disease receive a second induction course comprising daunorubicin IV over 30 minutes on days 1 and 2, cytarabine IV continuously on days 1-5, and oral PKC412 on the same schedule as their assigned treatment group. Patients with a complete response after course 1 or course 2 proceed to consolidation therapy.</div>
<div class="sdl3">  </div>
<div class="sdl3">    - Consolidation therapy: Patients in both groups receive high-dose cytarabine IV over 3 hours twice daily on days 1, 3, and 5 and oral PKC412 on the same schedule as their assigned treatment group. Treatment repeats every 28-42 days for 3 courses in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  After completion of consolidation therapy, patients in both groups continue to receive PKC412 alone, according to their assigned treatment group, every 28-42 days for up to 3 years in the absence of disease progression or unacceptable toxicity.</div>
<div class="sdl3">  </div>
<div class="sdl3">  Patients are followed every 3 months.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">  PROJECTED ACCRUAL: A total of 12-52 patients (6-26 per treatment group) will be accrued for this study.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2004-09</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 1</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with 11q23 (MLL) abnormalities</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with inv(16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(15;17)(q22;q12)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(16;16)(p13;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  adult acute myeloid leukemia with t(8;21)(q22;q22)</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  untreated adult acute myeloid leukemia</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  PKC412</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  cytarabine</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  daunorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemosensitization/potentiation</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  enzyme inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  high-dose chemotherapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Procedure</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  protein tyrosine kinase inhibitor therapy</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS: </div>
<div class="sdl4">    - Histologically confirmed acute myeloid leukemia (AML)</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Newly diagnosed disease</div>
<div class="sdl4">    - No history of or newly diagnosed myelodysplastic syndromes, history of myeloproliferative disease, or secondary AML</div>
<div class="sdl4">    - No CNS malignancy</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS: </div>
<div class="sdl4">  Age</div>
<div class="sdl4">    - 18 to 60</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status</div>
<div class="sdl4">    - Karnofsky 70-100%</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic</div>
<div class="sdl4">    - AST and ALT &amp;#8804; 1.5 times upper limit of normal (ULN)</div>
<div class="sdl4">    - Bilirubin &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No active viral hepatitis</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal</div>
<div class="sdl4">    - Creatinine &amp;#8804; 1.5 times ULN</div>
<div class="sdl4">    - No chronic renal disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular</div>
<div class="sdl4">    - Ejection fraction &amp;#8805; 50% by MUGA or echocardiogram</div>
<div class="sdl4">    - No congestive heart failure</div>
<div class="sdl4">    - No myocardial infarction within the past 6 months</div>
<div class="sdl4">    - No poorly controlled hypertension</div>
<div class="sdl4">    - No other cardiovascular disease</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary</div>
<div class="sdl4">    - No pulmonary infiltrate, including those suspected to be infectious</div>
<div class="sdl4">  </div>
<div class="sdl4">        - Patients with pulmonary infection whose clinical symptoms have resolved are eligible provided there are no residual pulmonary infiltrates on chest x-ray</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - No gastrointestinal impairment or disease that would preclude absorption of study drugs</div>
<div class="sdl4">    - No uncontrolled diabetes</div>
<div class="sdl4">    - No active uncontrolled infection</div>
<div class="sdl4">    - No other disease, except carcinoma , that would preclude study participation</div>
<div class="sdl4">    - No other severe or uncontrolled medical condition that would preclude study participation</div>
<div class="sdl4">    - HIV negative</div>
<div class="sdl4">    - Not pregnant or nursing</div>
<div class="sdl4">    - Negative pregnancy test</div>
<div class="sdl4">    - Fertile patients must use effective barrier contraception during and for 3 months after study participation</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR CONCURRENT THERAPY: </div>
<div class="sdl4">  Biologic therapy</div>
<div class="sdl4">    - At least 5 days since prior growth factors</div>
<div class="sdl4">    - No concurrent biological response modifiers</div>
<div class="sdl4">  </div>
<div class="sdl4">  Chemotherapy</div>
<div class="sdl4">    - No prior chemotherapy</div>
<div class="sdl4">    - No other concurrent chemotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Endocrine therapy</div>
<div class="sdl4">    - Not specified</div>
<div class="sdl4">  </div>
<div class="sdl4">  Radiotherapy</div>
<div class="sdl4">    - No prior radiotherapy except radiation castration</div>
<div class="sdl4">    - No concurrent radiotherapy</div>
<div class="sdl4">  </div>
<div class="sdl4">  Surgery</div>
<div class="sdl4">    - More than 14 days since prior surgical procedure except central venous catheter placement or other minor procedure (e.g., skin biopsy)</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other</div>
<div class="sdl4">    - More than 30 days since prior investigational agents</div>
<div class="sdl4">    - No other concurrent anticancer agents</div>
<div class="sdl4">    - No other concurrent investigational drugs</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  60 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Ronald Paquette, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Jonsson Comprehensive Cancer Center at UCLA</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Clinical trial summary from the National Cancer Institute&amp;apos;s PDQ&amp;#174; database</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://cancer.gov/clinicaltrials/UCLA-0308139-01</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2004-10-06</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2005-06-23</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f27');
SDiffDeclareUnchCRID('sdiff-collapse-f32');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m27');
SDiffDeclareUnchCRID('sdiff-collapse-m32');
SDiffInit();
</script></body></html>